Replies to post #21034 on RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Enemem, In retrospect, with all the time that has passed, they could have just redone the 900 and 1500 mg cohorts in RD-2, plus added another 2100 mg cohort to RD-2 that tested for maintenance of analgesia. Even with those additions, they would have had that data by now.